StockVS

Mobile-health Network Solutions (MNDR) Analyse boursière

Santé

Mobile-health Network Solutions

$0.77

$-0.09 (-10.27%)

Dernière mise à jour : 26 mai 2026

Historique des Prix

Analyse

Présentation de l'entreprise

Mobile-health Network Solutions (MNDR) operates as an investment holding company dedicated to delivering telehealth solutions, with its primary operational footprint located in Singapore. The entity functions within the broader Healthcare sector, specifically targeting the Health Information Services industry, which implies a focus on digitizing patient interactions and managing medical data infrastructure. The company maintains a workforce of 73 employees and holds a market capitalization of $3.10M, while reporting annual revenue of $7.32M. These financial metrics indicate a small-cap status, suggesting that the organization serves a niche segment of the market with limited resources compared to large-cap peers, yet it possesses the specialized expertise to operate a 360-degree healthcare ecosystem through its MaNaDr platform and segments in telemedicine and medical device sales.

Santé financière

The company recorded revenue of $7.32M over the trailing twelve months, yet reported a net income of -$2,586,343 and an EBITDA of -$2,503,371, highlighting a significant disparity between top-line growth and bottom-line profitability. The substantial gap between the $7.32M revenue and the negative net income reveals a cost structure where operating expenses severely outweigh gross profits, resulting in a loss that exceeds the total cash on hand of $3.48M. Although free cash flow is listed as N/A, the absence of positive cash generation from operations limits the company's financial flexibility and ability to fund expansion without external capital. The gross margin stands at 19.7%, indicating that the cost of goods sold consumes a significant portion of sales, while the operating margin of -22.2% and profit margin of -35.3% demonstrate that overhead costs and other expenses are eroding profitability at a rapid pace. The balance sheet shows a debt level of $115,463 against $3.48M in cash, supported by a debt-to-equity ratio of 1.39, which suggests a leveraged position where liabilities exceed equity, though the high current ratio of 4.22 indicates strong short-term liquidity to meet immediate obligations. Furthermore, the return on equity is -47.6% and the return on assets is -23.5%, metrics that reveal management is currently generating negative returns on the capital invested by shareholders and the assets utilized, reflecting the challenges of sustaining profitability in the current operational phase.

Évaluation de la valorisation

Trailing P/E and forward P/E ratios are both N/A due to the company's negative earnings, which implies that traditional earnings-based valuation metrics cannot be applied to assess the trajectory of expected earnings. The price-to-book ratio is 0.36, indicating that the market values the company at significantly less than its book value, suggesting a deep discount or potential undervaluation relative to the assets listed on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio of 0.42 and an EV/EBITDA of 0.16 suggest a very low multiple relative to revenue and enterprise value, reflecting the market's cautious stance on the company's current earnings power. The stock has traded within a 52-week range between a low of $0.76 and a high of $9.01, meaning the current price sits well below the 52-week high, reflecting significant volatility over the past year. The beta value is listed as N/A, which prevents a direct comparison of price volatility relative to the broader market index, though the wide spread between the 52-week high and low indicates high sensitivity to market conditions.

Growth & Income

Revenue growth year-over-year stands at -7.7%, while earnings growth is N/A due to negative earnings, indicating that the company is currently contracting rather than expanding its top line. Since the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it retains all earnings for reinvestment rather than distributing income to shareholders. The lack of dividend payments combined with negative earnings growth suggests that the company is prioritizing capital allocation toward operational restructuring or platform development over returning value to investors. Overall, the growth and income profile is characterized by contraction in revenue, a complete absence of cash dividends, and a reliance on retained earnings to potentially pivot the business toward profitability in the future.

Comparaison avec les pairs

Mobile-health Network Solutions (MNDR) opère dans le secteur Services d'Information Sanitaire. Voici comment il se compare à ses pairs les plus proches par capitalisation boursière :

Entreprise Ticker Cap. Boursière Ratio P/E
Mobile-health Network Solutions MNDR $5.52M N/A
Veeva Systems Inc. VEEV $25.87B 29.1
BrightSpring Health Services, Inc. BTSG $11.70B 78.3
Tempus AI, Inc. TEM $8.38B N/A

Le ratio P/E moyen du secteur Services d'Information Sanitaire est de 57.5x. Mobile-health Network Solutions se négocie à un P/E de N/A.

Cette analyse est générée par IA à titre informatif uniquement et ne constitue pas un conseil financier. Les données peuvent être retardées ou inexactes. Faites toujours vos propres recherches et consultez un conseiller financier qualifié avant de prendre des décisions d'investissement.

À propos de Mobile-health Network Solutions

Mobile-health Network Solutions, an investment holding company, provides telehealth solutions primarily in Singapore. The company operates in two segments: Telemedicine and Other Services and Sale of Medicine and Medical Devices. It offers MaNaDr platform, a 360-degree healthcare ecosystem, which connects users and service providers through the range of healthcare services and product offerings that can be accessed through the mobile application and website, as well as Internet search engines. The company also provides a suite of medical-related and other services, including teleconsultations and health check-up services, vaccinations, skin and aesthetics services, and other services. In addition, it offers healthcare and wellness products through its online e-commerce platform; wholesale distribution of pharmaceutical products to clinics through MaNaPharma platform; and MaNaCare, a platform that provides a range of corporate healthcare and wellness services, including GP, specialist and allied healthcare panel services, tele-consultation services, in-person clinics, on-site health screening, and online marketplace, as well as wellness programs to corporate customers. Further, the company develops IT systems on mobile phone and web portals; operates pharmacies, clinics, and drug stores; and offers beauty and other personal care services, as well as other general medical services. Additionally, it offers health supplements, skincare, nutrition products and medical devices wellness, personal care; health screening packages; and online services such as medical screenings and procedures, such as serology and swab tests. The company was founded in 2009 and is headquartered in Singapore.

La description de l'entreprise est affichée en anglais.

Visiter le site →

Statistiques Clés

Capitalisation
$5.52M
Ratio P/E
N/A
Plus Haut 52 Sem.
$7.95
Plus Bas 52 Sem.
$0.66
Volume Moyen
2.68M
Bêta
-1.29

Données fournies par Yahoo Finance via yfinance. Mis à jour quotidiennement.

Info Entreprise

Bourse
NASDAQ
Pays
Singapore
Employés
73